NCT07351162
Not yet recruiting
Not Applicable
Hypertension Treatment in Nigeria Program 2.0
Washington University School of Medicine0 sites10,000 target enrollmentStarted: February 1, 2026Last updated:
Overview
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 10,000
Overview
Brief Summary
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory, Nigeria. This program demonstrated significant improvements in hypertension treatment and control. HTN 2.0 will expand implementation of the HEARTS bundle to 5 new states in 5 geopolitical zones in Nigeria (Abia, Delta, Gombe, Jigawa, and Oyo) while also evaluating sustainment of hypertension control in the Federal Capital Territory.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Health Services Research
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adults (≥18 years old),
- •Elevated blood pressure (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) documented or measured by a health care professional (e.g., physician, community health extension worker, or community health officer) on two separate occasions or taking a BP-lowering medication, or a history of hypertension.
- •Pregnant women are eligible for this program, or
- •Cognitively impaired adults are eligible for this program..
Exclusion Criteria
- •This program will not include any of the following special populations:
- •Individuals who are not yet adults (minors): i.e. infants, children, or teenagers \<18 years old, or
- •Prisoners or other detained individuals.
Investigators
Mark Huffman
William Bowen Professor of Medicine, Professor of Public Health, Co-Director Global Health Center and Global Health Futures
Washington University School of Medicine
Similar Trials
Active, not recruiting
Phase 1
A Phase 2, Open-Label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal HemoglobinuriaEUCTR2015-002674-20-DEAlexion Pharmaceuticals, Inc.26
Active, not recruiting
Phase 1
A Phase 2, Open-Label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)MedDRA version: 18.0Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2015-002674-20-ESAlexion Pharmaceuticals, Inc.26
Active, not recruiting
Phase 1
A Phase 2, Open-Label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)MedDRA version: 18.0Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2015-002674-20-SEAlexion Pharmaceuticals, Inc.26
Active, not recruiting
Phase 1
A Phase 2, Open-Label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)MedDRA version: 21.1 Level: LLT Classification code 10055629 Term: Paroxysmal nocturnal hemoglobinuria System Organ Class: 100000004857Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2015-002674-20-GBAlexion Pharmaceuticals, Inc.26
Recruiting
Phase 2
A Phase II, Open-label, Multicenter, Translational Study for Biomarkers of Eribulin Mesylate: Evaluation of the Utility of Monitoring Epithelial-to-Mesenchymal Transition (EMT) Markers on Tumor Cells in the Malignant Plural Effusion of Patients with Metastatic Breast CancerMetastatic Breast CancerJPRN-UMIN000022362Shizuoka Cancer Center48